General MedicationsSubcutaneousStandard
BRAVELLE
UROFOLLITROPIN
Standard Dose
0.9%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BRAVELLE is listed in Drugs@FDA under application 021484 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient UROFOLLITROPIN Form and strength Injectable; Subcutaneous - 0.9% Sponsor FERRING Submission history Latest submission status date: 2002-12-19 00:00:00.
Structured Monograph
Clinical summary
Approval overview BRAVELLE is listed in Drugs@FDA under application 021484 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient UROFOLLITROPIN Form and strength Injectable; Subcutaneous - 0.9% Sponsor FERRING Submission history Latest submission status date: 2002-12-19 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.